

Harm, Discretion or Duty: the Changing Nature of the Return of Individualized Results in Genomics Research

The Legal and Ethical Challenges of
Precision Medicine

Alison Hall
April 08 2016



The PHG Foundation

The PHG Foundation is a UK independent think-tank in with a special focus on **genomics** and other **emerging health technologies** that can provide more accurate and effective personalised medicine.

MISSION - to make science work for health

- We provide knowledge, evidence, tools and opportunities for policymakers to deliver rational and responsible changes in health policy and practice
- Member of Cambridge University Health Partners and Cambridge Institute of Public Health
- Active since 1997



Emerging questions about return of results in genomic research

? Normative

Should individualized genomic results be returned?

? Ethical

How can this be done in an ethical manner?: provide benefit, not be harmful, promote autonomy, and justice

? Legal

Compatible with existing legal principles, regulation and governance



Return of individualized results in genomics

'Return'

- Miss-description
- *Informing* a research participant (or their legal representative) of results of tests performed as part of the research

'**Genomics**' the study of all of a person's genes (the genome), including interactions of those genes with each other and with the person's environment.

Return of individualized results?

'Pertinent'


Findings relating to the primary purpose

'Incidental'

A finding concerning an individual research participant that has *potential health or reproductive importance* and is *discovered* in the course of conducting research but is beyond the aims of the study. This means that IFs may be on variables not directly under study and may not be anticipated in the research protocol (Wolf et al)

Table 4

Recommended Pathway for Handling IFs in Research



Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations

Susan M. Wolf,
Frances P. Lawrenz,
Charles A. Nelson,
Jeffrey P. Kahn, Mildred K. Cho,
Ellen Wright Clayton,
Joel G. Fletcher,
Michael K. Georgieff,
Dale Hammerschmidt,
Kathy Hudson, Judy Illes,
Vivek Kapur, Moira A. Keane,
Barbara A. Koenig,
Bonnie S. LeRoy,
Elizabeth G. McFarland,
Jordan Paradise, Lisa S. Parker,
Sharon F. Terry, Brian Van Ness,
and Benjamin S. Wilfond

Wolf et al: recommended classification (2008) (summary)

Category	Relevant incidental findings	Recommended action
Strong net benefit	<ul style="list-style-type: none">• Condition likely to be life threatening• Grave condition that can be avoided or ameliorated• Significant risk of a condition likely to be life-threatening• To avoid or ameliorate a condition likely to be grave• Reproductive decision making to avoid or ameliorate a significant risk of offspring having a life-threatening or grave condition	Disclose unless P elected not to know
Possible net benefit	<ul style="list-style-type: none">• Non fatal grave or serious condition which cannot be avoided or ameliorated (likely to be viewed as important)• Significant risk of a non-modifiable grave or serious condition (likely to be viewed as important)• Reproductive decision making to avoid or ameliorate offspring having a condition likely to be serious	May disclose unless P elected not to know
Unlikely net benefit	<ul style="list-style-type: none">• A condition not likely to be of serious health or reproductive importance• Condition whose likely health or reproductive importance cannot be ascertained	Do not disclose


Return of individualized results?

'Secondary'

Findings that are *anticipated* and *can be actively sought* with a given procedure, but are not the *primary* target of the research evaluation

Presidential Commission for the Study of Bioethical Issues 2013

Context-Specific Recommendations
Clinical Recommendations
<i>Consent in the Clinical Context</i>
<i>Empirical Data in the Clinical Context</i>
<i>Clinical Judgement in Managing Incidental Findings</i>
Research Recommendations
<i>Consent in the Research Context</i>
<i>Planning for Incidental Findings in Research</i>
<i>No Duty to Look for Secondary Findings in Research</i>
Direct-to-Consumer Recommendations
<i>Consent in the Direct-to-Consumer Context</i>
<i>Government Regulation in the Direct-to-Consumer Context</i>
<i>Industry-Wide Best Practices in the Direct-to-Consumer Context</i>



Return of individualized results?

Additional 'looked for' findings

Genomic changes that are *unrelated* to the cancer or rare disease, and *known* to cause serious, life threatening conditions. 1:100 will have one of these conditions



- Estimates of 1-3% 'high risk of serious disease that could be mitigated by timely medical intervention



Darnett AJ et al (2016) A Clinical Service to Support the Return of Secondary Genomic Findings in Human Research AJHG 98, 435-441 March 3 2016

- 1% candidate variants in the 56 ACMG genes (1000 Genomes dataset)



Olfson E et al (2015) Identification of Medically Actionable Secondary Findings in the 1000 Genomes Plos One Sep 2 10(9):e0135193

- But the relationship between genotype and phenotype likely to be 'promiscuous'

Lu JT et al (2014) Genotype-Phenotype Correlation – Promiscuity in the Era of Next Generation Sequencing NEJM DOI:10.1056/NEJMp1400788



The inexorable change in responsibilities around 'return' of results

Scientific validity

Validation
Quality Assurance

Clinical utility

Distinguishing subtypes

Operationalising return

'No surprises'
Consent processes

Defining scope

Extent of duty
Logistics for re-contact and return

Return of individualized results can be harmful

Return of individualized results can sometimes be justified

There is a duty to return 'incidental' clinically actionable research results

There is a duty to generate and return clinically actionable research results

Time →

The nature of that responsibility

Non-maleficence ***Paternalism***

Release of data has potential to cause distress

Beneficence ***Infrastructures***

Protocols
Information sheets
Consent forms

Justice ***Elements***

Provision
Expertise
Insurance
Funding

Respect for Autonomy ***Looking beyond participants***

- Children
- Biological

To keep data **secure** and utilise solely for research purposes

Protocols and materials for dealing with potential release of individualised results

Methodology for
- **Validation**
- **Referral**

Integrated processes for generating and releasing individualized results

Time →

The current position (1)

- Literature and policy review
- Empirical research with stakeholders

Sénécal et al Statement of Principles on the Return of Research Results and Incidental Findings in Paediatric Research: A Multi-site Consultative Process DOI:10.1139/gene-2015-0092

- 'a continuum of decisions to return research results depending on numerous contextual factors
 - Best interests of children
 - Clinical significance of findings
 - Need to adhere to professional standards
 - Obligations should not extend beyond the duration of the research

Rahimzadeh V et al (2015) To disclose, or not to disclose? Context matters *EJHG* (2015) 23,279-284



The current position (2)

- A plethora of guidelines acknowledging the potential for communicating individualized results
- *Empirical work*
 - Marked differences between stakeholder groups
 - Participants tend to favour disclosure even if findings are not clinically significant
 - Willingness amongst research ethics committees to countenance feedback BUT limitations are lack of skills and resources to identify, verify, interpret and return results

Darnell et al A Clinical Service to Support the Return of Secondary Genomic Findings in Human Research <http://dx.doi.org/10.1016/j.ajhg.2016.01.010>

- In the short term – practices are likely to be:
 - Highly variable
 - Potentially detrimental effect

What are the principles governing desirability of return ?

A Clinical Service to Support the Return of Secondary Genomic Findings in Human Research

Relevant
Legal
Principles

Duty of care

Potential
clinical
utility

Proximity





Figure 1. Graphical Representation of Some Key Attributes of Research Studies that Argue For or Against Seeking and Returning Secondary Findings

Andrew J. Darnell et al et al
<http://dx.doi.org/10.1016/j.ajhg.2016.01.010>

How might a duty to return individualized research results be characterised?

- Is this a normative obligation or legal duty?
- What form of duty (care, warn or rescue)
- By whom is it owed? (interpretation and disclosure are multidisciplinary activities)
- To whom is the duty owed?
- What could it involve?
 - Examining data for secondary and incidental findings (and relevant pertinent findings)
 - Stipulating the actions to be taken (e.g. to validate/refer)
 - Setting out what research participants are told and when
 - Provision for guardian/legal representatives
 - Full descriptions in protocols/apportioning liability



What is the likelihood of such a duty developing? *And bringing a successful claim?*

Montgomery v Lanarkshire Health Board [2015]

- Is a duty 'fair, just and reasonable'?
- *Montgomery* – 'risks are patient-centred'
- Displaces *Bolam* – 'to exercise the care and skill of a reasonable professional'
- Applied **different tests** to **risk communication** and to **treatment/diagnosis**
- The obligations arising in **clinical care** and **research** are very different but the **boundaries** between these activities are often **blurred**
- Increasing instances of generating and disclosing **clinically actionable results** (whether pertinent, secondary or incidental) in **genomic research**
- **Clinical care** and **research** practice are becoming inexorably **linked**



What thresholds must be met to establish liability for negligent non-disclosure?

- **Duty**
 - **Breach**
 - **Damage**
- Successful claims unlikely
Duty to exercise reasonable skill
'Informational harm'



Colin Mitchell, Helex 2016

Two ways in which liability for non-negligent disclosure in genomic research could arise:

- (a) Greater personalization of the genomic sequencing process in research
- (b) A failure to communicate clinically actionable individualized findings to family members in specified cases



phg

foundation
making science
work for health

Potential impacts of personalization of the return of results in genomic research

Elements of personalization might include:

- Inviting participants to **select** genes, disorders or categories in advance of **secondary findings analysis**
- **Dictating the scale and timing of return** (other than respecting a 'right not to know')

If this results in:

- Increased '**quasi clinical**' contact between researcher and participant
- **Tailored generation, analysis and feedback of results**
- **Heightened visibility** ('service' performed with reasonable skill without breaches)

➤ Might imply that a **duty of care** exists

Extending the duty of care to relatives

A **duty of care** may be more likely to be recognized:

- Especially unclear **boundaries** between clinical care and research
- Close **biological relatedness** with the participant
- Where the family member is a **parent** or **guardian**
- **Foreseeable** harm (disease penetrance/ timeliness)
- Where the research participant has **died**

ABC v St George's Healthcare NHS Trust & Others 2015 (UK)

- Duty to families rather than individuals
- Requires a balance between right to confidentiality and risk of harm to others
- Possible emergence of a duty to consider warning relatives and exercise reasonable skill and judgment



Implications for practice

FOR THE SECTOR

- Need harmonized, multidisciplinary approaches
- Clarity - nature of the activity and its objectives
- Legally and ethically sound
- Build expertise within IRB/RECs
- Transparent and accountable (to build trust)



FOR INDIVIDUAL RESEARCHERS

- Consistent with existing legal principles, regulation and governance
- Strong leadership and appropriate clinical support
- Accessible patient facing materials (PIS, consent forms)
- Consider reasonable expectations of participants
- Provision for disclosure in funding, insurance

Summary

- Existing terminology is unhelpful and misleading
- Current proliferation of practices is likely to lead to inconsistencies
- Adopting more personalized approaches to communicating individualized research results could have unintended impacts
- Need for proactive policy development at a global level



phgfoundation

making science work for health



CAMBRIDGE UNIVERSITY
Health Partners

Knowledge-based healthcare

alison.hall@phgfoundation.org